Tadalafil (Cialis) is NOT indicated for treating systemic hypertension and should not be used for this purpose
Tadalafil is FDA-approved only for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH)—not for systemic hypertension management 1. While it does lower blood pressure as a side effect, this is not a therapeutic indication and using it for hypertension control would be off-label and inappropriate.
Why Tadalafil Should Not Be Used for Systemic Hypertension
Blood Pressure Effects Are Modest and Unpredictable
- Tadalafil 20 mg produces only small reductions in blood pressure: approximately 4.8/2.9 mmHg in hypertensive patients overall 2
- In healthy subjects, tadalafil 20 mg showed minimal effects with mean maximal decreases of only 1.6/0.8 mmHg supine and 0.2/4.6 mmHg standing 1
- These effects are inconsistent and far less reliable than established antihypertensive medications
Dangerous Drug Interactions
The most critical concern is the absolute contraindication with nitrates 1. Tadalafil potentiates nitrate-induced hypotension significantly:
- When combined with sublingual nitroglycerin, tadalafil causes dangerous blood pressure drops (mean maximal standing systolic BP decrease of -36 mmHg with tadalafil 5 mg) 3
- This interaction persists for at least 24-48 hours after tadalafil administration 1
- If a patient takes tadalafil, nitrates cannot be safely administered for at least 48 hours—a major problem in cardiovascular emergencies 1
Better Alternatives Exist
Standard antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) provide:
- Predictable, dose-dependent BP reduction
- Proven mortality and morbidity benefits
- No contraindication with emergency cardiac medications
- Better tolerability profiles for chronic use
The Only Cardiovascular Indication: Pulmonary Arterial Hypertension
Tadalafil IS approved for PAH at doses of 20-40 mg daily 4, 5. This is a completely different disease process affecting pulmonary vascular resistance, not systemic blood pressure. The mechanism involves PDE5 inhibition in pulmonary smooth muscle, improving right ventricular afterload 4.
What the Evidence Actually Shows
The Princeton III Consensus 6 notes that PDE5 inhibitors like tadalafil have "demonstrated a potential role in the management of hypertension and endothelial dysfunction," but this refers to research interest, not clinical recommendation. The consensus emphasizes that "management of ED should always be considered secondary to maintaining cardiovascular function" 6.
Research studies showing BP reduction 2 were designed to assess safety in hypertensive patients taking tadalafil for ED, not to establish efficacy for hypertension treatment. The 7.5/4.3 mmHg reduction seen in uncontrolled hypertensive patients 2 is insufficient for adequate BP control and would never replace proper antihypertensive therapy.
Clinical Bottom Line
If your patient has controlled hypertension and needs ED treatment, tadalafil is safe to use at standard ED doses (10-20 mg as needed, or 2.5-5 mg daily) 1, 7. The drug is well-tolerated in patients on multiple antihypertensive agents 7, 8.
However, never prescribe tadalafil with the primary goal of lowering systemic blood pressure. Use evidence-based antihypertensive medications that have proven cardiovascular benefits and don't create dangerous contraindications to emergency cardiac care.